Raymond Wadlow

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer
    Topic:
    Colorectal cancer
    Date added:
    05/20/2023
    Date updated:
    05/20/2023
    Relationship end date:
    03/28/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Seagen
    Topic:
    Colorectal cancer
    Date added:
    05/20/2023
    Date updated:
    05/20/2023
    Relationship end date:
    10/24/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Exact Sciences
    Topic:
    Colorectal cancer
    Date added:
    05/20/2023
    Date updated:
    05/20/2023
    Relationship end date:
    01/25/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Taiho
    Topic:
    Colorectal cancer
    Date added:
    05/20/2023
    Date updated:
    05/20/2023
    Relationship end date:
    03/30/2023
  • Attribution:
    Spouse or Partner
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Johnson & Johnson
    Topic:
    Lung cancer
    Date added:
    05/20/2023
    Date updated:
    05/20/2023
Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond